Disparities in subgroup populations enrolled in lung cancer trials

References

• Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years, analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol.24(28), 4539–4544 (2006).
   PubMed Web of Science ®Google Scholar
• Felip E, Gridelli C, Baas P, Rosell R, Stahel R. Metastatic non-small-cell lung cancer, consensus on pathology and molecular tests, first-line, second-line, and third-line therapy, 1st ESMO Consensus Conference in lung cancer; Lugano 2010. Ann. Oncol.22(7), 1507–1519 (2011).
   PubMed Web of Science ®Google Scholar
• Stahel R, Thatcher N, Früh M et al. 1st ESMO Consensus Conference in lung cancer; Lugano 2010, small-cell lung cancer. Ann. Oncol.22(9), 1973–1980 (2011).
   PubMed Web of Science ®Google Scholar
• Sateren WB, Trimble EL, Abrams J et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J. Clin. Oncol.20(8), 2109–2117 (2002).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol.18(10), 2085–2103 (2000).
   Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN et al. Randomized Phase 3 trial of docetaxel versus vinorelbine or ifosfamide in patients with non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. Clin. Oncol.18(12), 2354–2362 (2000).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase 3 trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22, 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med.353, 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer, results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet366, 1527–1537 (2005).
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST), a randomised Phase 3 trial. Lancet327(9652), 1809–1818 (2008).
   Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P et al. Phase 3 trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer, AVAil. J. Clin. Oncol.27(8), 1227–1234 (2009).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J et al. Phase 3 study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol.26(21), 3543–3551 (2008).
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX), an open-label randomized Phase 3 trial. Lancet373(9674), 1525–1531 (2009).
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med.362(25), 2380–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405), an open label, randomised Phase 3 trial. Lancet Oncol.11(2), 121–128 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu TL, Chen G et al. Erlotinib versus chemotherapy as first-line therapy for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802), a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol.12(8), 735–742 (2011).
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC), a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol.13(3), 239–246 (2012).
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer, a randomised, double-blind, Phase 3 study. Lancet374(9699), 1432–1440 (2009).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer, a multicentre, randomised, placebo-controlled Phase 3 study. Lancet Oncol.11(6), 521–529 (2010).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, de Marinis F, Dediu M et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, Phase 3, randomised controlled trial. Lancet Oncol.13(3), 247–255 (2012).
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Ragin CC, Belani CP et al. Lung cancer in elderly patients, an analysis of the surveillance, epidemiology, and end results database. J. Clin. Oncol.25(35), 5570–5577 (2007).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Dahlberg SE, Gray RJ et al. Sex differences in outcome with bevacizumab therapy, analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group trial 4599. J. Thorac. Oncol.6(1), 103–108 (2011).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer, results from a randomised Phase 3 trial (AVAiL). Ann. Oncol.21(9), 1804–1809 (2010).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer, results of the randomized multicenter Phase 3 trial BMS099. J. Clin. Oncol.28(6), 911–917 (2010).
   PubMed Web of Science ®Google Scholar
• Mountain JL, Cavalli-Sforza LL. Multilocus genotypes, a tree of individuals, and human evolutionary history. Am. J. Hum. Genet.61(3), 705–718 (1997).
   PubMed Web of Science ®Google Scholar
• Goodman AH. Why genes don’t count (for racial differences in health). Am. J. Public Health90(11), 1699–1702 (2000).
   PubMed Web of Science ®Google Scholar
• Hanna N, Bunn PA, Langer C et al. Randomized Phase 3 trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol.24(13), 2038–2043 (2006).
   PubMed Web of Science ®Google Scholar
• Beutler E, Gelbart E, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promote; a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA95(14), 8170–8174 (1998).
   PubMed Web of Science ®Google Scholar
• Font A, Sanchez JM, Taron M et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest. New Drugs21(4), 435–443 (2003).
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation112(24), 3754–3762 (2005).
   PubMed Web of Science ®Google Scholar
• Kelsey KT, Ross D, Traver RD et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br. J. Cancer76(7), 852–854 (1997).
   PubMed Web of Science ®Google Scholar
• Yancik R. Population aging and cancer, a cross-national concern. Cancer J.11(6), 437–441 (2005).
   PubMed Web of Science ®Google Scholar
• Yancik R, Ries LA. Cancer in older persons, an international issue in an aging world. Semin. Oncol.31(2), 128–136 (2004).
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med.341(27), 2061–2067 (1999).
   PubMed Web of Science ®Google Scholar
• Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J. Clin. Oncol.21(7), 1383–1389 (2003).
   PubMed Web of Science ®Google Scholar
• Yee KW, Pater JL, Pho L, Zee B, Siu LL. Enrolment of older patients in cancer treatment trials in Canada, why is age a barrier? J. Clin. Oncol.21(8), 1618–1623 (2003).
   PubMed Web of Science ®Google Scholar
• Talarico L, Chen G, Pazdur R. Enrolment of elderly patients in clinical trials for cancer drug registration, a 7-year experience by the US Food and Drug Administration. J. Clin. Oncol.22(22), 4626–4631 (2004).
   PubMed Web of Science ®Google Scholar
• Balducci L. Geriatric oncology, challenges for the new century. Eur. J. Cancer36(14), 1741–1754 (2000).
   PubMed Web of Science ®Google Scholar
• Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol.16(4), 1582–1587 (1998).
   PubMed Web of Science ®Google Scholar
• Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer67(12), 3131–3135 (1991).
   PubMed Web of Science ®Google Scholar
• Litchman SM, Villani G. Chemotherapy in the elderly, pharmacologic considerations. Cancer Control7(6), 548–556 (2000).
   PubMedGoogle Scholar
• Jatoi A, Hillman S, Stella P et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J. Clin. Oncol.23(36), 9113–9119 (2005).
   PubMed Web of Science ®Google Scholar
• Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J. Clin. Oncol.23(13), 3112–3124 (2005).
   PubMed Web of Science ®Google Scholar
• Basche M, Baron A, Eckhardt SG et al. Barriers to enrollment of elderly adults in early-phase cancer clinical trials. J. Oncol. Pract.4(4), 162–168 (2008).
   PubMedGoogle Scholar
• Langer CJ, Vangel J, Schiller DP et al. Age-specific subanalysis of ECOG 1594, fit elderly patients (70–80 yrs) with NSCLC do as well as younger patients (<70). Presented at: 39th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 31 May–3 June 2003.
   Google Scholar
• Belani CP, Fossella F. Elderly subgroup analysis of a randomized Phase 3 study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer104(12), 2766–2774 (2005).
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Perry MC, La Rocca RV et al. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer113(3), 542–546 (2008).
   PubMed Web of Science ®Google Scholar
• Blanchard EM, Moon J, Hesketh PJ et al. Comparison of platinum-based chemotherapy in patients older and younger than 70 years, an analysis of Southwest Oncology Group trials 9308 and 9509. J. Thorac. Oncol.6(1), 115–120 (2011).
   PubMed Web of Science ®Google Scholar
• Rossi A. Elderly patients with advanced non-small cell lung cancer, what treatment? Open Lung Cancer J.4, 4–9 (2011).
   Google Scholar
• Kawk EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363(18), 1693–1703 (2010).
   PubMed Web of Science ®Google Scholar